 |
autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2â⿬⿢-deoxycytidine |
|---|---|
| Trade Name | Alecsat |
| Orphan Indication | Glioblastoma multiforme |
| USA Market Approval | USA |
| USA Designation Date | 2013-09-13 00:00:00 |
| Sponsor | CytoVac A/S;Science & Technology Park Scion DTU, DK-2970;Horsholm |
